BR112013002641A2 - formulação de micropartículas para administração de medicamentos pulmonares de molécula anti-infeccionais para tratamento de doenças infecciosas - Google Patents

formulação de micropartículas para administração de medicamentos pulmonares de molécula anti-infeccionais para tratamento de doenças infecciosas

Info

Publication number
BR112013002641A2
BR112013002641A2 BR112013002641A BR112013002641A BR112013002641A2 BR 112013002641 A2 BR112013002641 A2 BR 112013002641A2 BR 112013002641 A BR112013002641 A BR 112013002641A BR 112013002641 A BR112013002641 A BR 112013002641A BR 112013002641 A2 BR112013002641 A2 BR 112013002641A2
Authority
BR
Brazil
Prior art keywords
formulation
administration
pulmonary
microparticles
treatment
Prior art date
Application number
BR112013002641A
Other languages
English (en)
Portuguese (pt)
Inventor
Aravindan Vasudevan
Geetanjali Chandrashekhar Chimote
Girish Badrinath Mahajan
Sivaramakrishnan Hariharan
Original Assignee
Piramal Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Entpr Ltd filed Critical Piramal Entpr Ltd
Publication of BR112013002641A2 publication Critical patent/BR112013002641A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013002641A 2010-08-05 2011-08-04 formulação de micropartículas para administração de medicamentos pulmonares de molécula anti-infeccionais para tratamento de doenças infecciosas BR112013002641A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37091610P 2010-08-05 2010-08-05
PCT/IB2011/053470 WO2012017405A1 (en) 2010-08-05 2011-08-04 Microparticle formulation for pulmonary drug delivery of anti-infective molecule for treatment of infectious diseases

Publications (1)

Publication Number Publication Date
BR112013002641A2 true BR112013002641A2 (pt) 2016-06-07

Family

ID=44653372

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013002641A BR112013002641A2 (pt) 2010-08-05 2011-08-04 formulação de micropartículas para administração de medicamentos pulmonares de molécula anti-infeccionais para tratamento de doenças infecciosas

Country Status (14)

Country Link
US (1) US8697653B2 (https=)
EP (1) EP2600842A1 (https=)
JP (1) JP2013532722A (https=)
KR (1) KR20130109106A (https=)
CN (1) CN103442694B (https=)
AU (1) AU2011287205A1 (https=)
BR (1) BR112013002641A2 (https=)
CA (1) CA2807357A1 (https=)
IN (1) IN2013MN00329A (https=)
MX (1) MX2013001325A (https=)
RU (1) RU2013109384A (https=)
TW (1) TW201208716A (https=)
WO (1) WO2012017405A1 (https=)
ZA (1) ZA201301662B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015107482A1 (en) * 2014-01-17 2015-07-23 Piramal Enterprises Limited Pharmaceutical combination for treatment of tuberculosis
US10335374B2 (en) 2014-12-04 2019-07-02 University System of Georgia, Valdosta State University Tablet composition for anti-tuberculosis antibiotics
CN109827875A (zh) * 2019-04-10 2019-05-31 上海市食品药品检验所 一种用于测定吸入制剂溶出度的装置和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8601457D0 (sv) * 1986-04-01 1986-04-01 Draco Ab Compositions of liposomes and b?712-receptor active substances for inhalation
JPH0751496B2 (ja) * 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
TW497974B (en) * 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
KR20010111564A (ko) * 1998-11-12 2001-12-19 프랭크 쥐. 필키윅즈 흡입 시스템
EP1255548A4 (en) 2000-01-31 2004-10-06 Eisai Co Ltd USE OF THIOSTREPTON AS AN ACTIVE AGAINST MYCOBACTERIES
JP2005530704A (ja) * 2002-03-05 2005-10-13 トランセイブ, インク. 細胞内感染を予防及び治療するための吸入システム
JP2010515753A (ja) * 2007-01-10 2010-05-13 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 肺内送達用免疫抑制剤組成物の送達の増強
RU2536587C2 (ru) 2009-09-02 2014-12-27 Пирамал Энтерпрайзис Лимитед Антибиотические соединения

Also Published As

Publication number Publication date
IN2013MN00329A (https=) 2015-05-29
EP2600842A1 (en) 2013-06-12
KR20130109106A (ko) 2013-10-07
RU2013109384A (ru) 2014-09-10
TW201208716A (en) 2012-03-01
ZA201301662B (en) 2014-08-27
US8697653B2 (en) 2014-04-15
CN103442694A (zh) 2013-12-11
CA2807357A1 (en) 2012-02-09
AU2011287205A1 (en) 2013-03-07
MX2013001325A (es) 2013-10-28
WO2012017405A1 (en) 2012-02-09
JP2013532722A (ja) 2013-08-19
CN103442694B (zh) 2015-09-09
US20130125879A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
Bassetti et al. Inhaled liposomal antimicrobial delivery in lung infections
BR112015012351A8 (pt) composição de antibiótico de glicopeptídeo à base de lipídeo estabilizado e uso de um componente lipídico, um componente de antibiótico de glicopeptídeo e um aminoácido ou derivado do mesmo
Ding et al. Antiviral activity of baicalin against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase
BR112014029010A2 (pt) sistemas para tratamento de infecções pulmonares
Suh et al. Biofilms
MX2012012225A (es) Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
US20230124862A1 (en) Bismuth thiol compounds and compositions and methods of treating microbial co-infections
Cipolla et al. Inhaled antibiotics to treat lung infection
BR112022014578A2 (pt) Composição e métodos de profiláticos e terapêuticos de rnai para o tratamento de infecção respiratória aguda grave causada pelo novo coronavírus 2019 (2019-ncov)
GT201400016A (es) Indazoles
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
CN104602672A (zh) 用于治疗细菌感染的定制脂质体
BR112015009913A2 (pt) composições farmacêuticas para o tratamento de doenças mediadas por cftr
BR112013029692A2 (pt) derivados de imidazol úteis para o tratamento da artrite
BR112014029735A2 (pt) forma de dosagem e formulação de abediterol
BR112015007647A2 (pt) derivados de quetamina
BRPI0915942A2 (pt) método para produção de compostos medicinais contendo dabigatrana
BR112013002641A2 (pt) formulação de micropartículas para administração de medicamentos pulmonares de molécula anti-infeccionais para tratamento de doenças infecciosas
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
BR112017020039A2 (pt) composição farmacêutica, kit, método, processo para preparar uma composição e solução farmacêutica
JP2022531929A5 (https=)
BRPI0719920B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário
GB2577419A (en) Lipo-glycopeptide cleavable derivatives and uses thereof
Schwarz Colobreathe® for the treatment of cystic fibrosis-associated pulmonary infections
BR112012011017A2 (pt) processos e composições para tratamento rápido de otite externa

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]